Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Malnutrition and inappropriate prescribing of renally excreted drugs are common among older
persons and are associated with severe consequences such as complicated courses of treatment,
mortality, and reduced quality of life. The overall purpose of CanPan is to optimize
treatment of older persons with malnutrition with a focus on appetite stimulation and
optimized prescribing of renal risk drugs.
The CanPan trial consists of two sub-studies. Substudy 1 will provide knowledge on appetite
and appetite stimulation and together, sub study 1 and 2 will offer unique knowledge on how
body composition, renal function and biomarkers of organ function influence pharmacokinetics
for a highly lipophilic (Sativex®) and hydrophilic (Hexamycin®) drug in older medical
patients with malnutrition.
Phase:
Phase 1
Details
Lead Sponsor:
Ove Andersen
Collaborators:
Glostrup University Hospital, Copenhagen North Denmark Regional Hospital Region Hovedstadens Apotek University Hospital Bispebjerg and Frederiksberg University of Copenhagen